Portal de Periódicos da CAPES

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

2014; Elsevier BV; Volume: 124; Issue: 19 Linguagem: Inglês

10.1182/blood-2014-08-596668

1528-0020

Giuseppe Visani, Pietro Maria Stefani, Saveria Capria, Lara Malerba, Piero Galieni, Francesco Gaudio, Giorgina Specchia, Giovanna Meloni, Filíppo Gherlinzoni, Roberta Gonella, Marco Gobbi, Armando Santoro, Felicetto Ferrara, Marco Rocchi, Enrique M. Ocio, Marı́a Dolores Caballero, Federica Loscocco, Alessandro Isidori,

Chronic Lymphocytic Leukemia Research

To the editor: Based on the results of the PARMA and CORAL studies, high-dose chemotherapy (HDT) followed by autologous stem cell rescue has become the standard of care for patients with relapsed, chemosensitive aggressive non-Hodgkin lymphoma (NHL).[1][1],[2][2] Moreover, HDT/autologous stem cell